Product Program year 2019 Source: CMS Open Payments

Cablivi

Drug Rare Blood Disorders

NDC 58468-0225-1

Open in the dashboard

General payments

$239,556

976 payments

Research payments

$62,314

45 payments

Through program year 2019, $239,556 in general payments and $62,314 in research payments were reported against Cablivi (Rare Blood Disorders).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $239,556 976
2019 Research $62,314 45

Breakdown

Who paid General payments · program year 2019
  1. Genzyme Corporation $234,895 911 payments
  2. Bioverativ Therapeutics Inc. $2,355 1 payment
  3. Sanofi-Aventis U.S. LLC $2,306 64 payments
Top recipients General payments · program year 2019
  1. Jay Raval Blood Banking & Transfusion Medicine · Los Ranchos, NM $53,763 22% · 27 payments
  2. Spero Cataland Hematology · Columbus, OH $31,347 13% · 12 payments
  3. Jamile Shammo Hematology & Oncology · Chicago, IL $30,713 13% · 25 payments
  4. Yulian Khagi Hematology & Oncology · Laguna Hills, CA $24,908 10% · 23 payments
  5. Ara Metjian Hematology & Oncology · Aurora, CO $9,619 4% · 7 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Hematology & Oncology Internal Medicine $88,190 40% · 312 practitioners
  2. Blood Banking & Transfusion Medicine Pathology $61,621 28% · 11 practitioners
  3. Hematology Internal Medicine $44,998 20% · 25 practitioners
  4. Internal Medicine $14,239 6% · 33 practitioners
  5. Anatomic Pathology & Clinical Pathology Pathology $7,671 3% · 10 practitioners

The top 5 of 34 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. New Mexico $53,763 22% · 1 recipient
  2. Ohio $40,594 17% · 9 recipients
  3. California $37,555 16% · 158 recipients
  4. Illinois $31,460 13% · 32 recipients
  5. Alabama $14,965 6% · 4 recipients

The top 5 of 39 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

25

Prescriptions dispensed, refills included

Drug cost

$6,138,425

Paid at the pharmacy, in all

Prescribers

2

With 11 or more claims of it

Medicare Part D drugs matched to CABLIVI, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Cablivi Caplacizumab-Yhdp Same name 2 25 $6,138,425

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

2 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Charity Eck Nurse Practitioner PA 13 $3,192,051 None on record
Stephen Divers Medical Oncology AR 12 $2,946,374 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

976 general · 45 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record